Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

celebratelife May. 20 at 3:04 PM

$KPTI Paulson in his new suit? As usual he added zero value. Reshma practically handled the whole thing, and she could have done 100% fine without him but it cost us a lot of money to get him down there. You can be he's not the type who's economical on expenses. His new mantra of "financial discipline" after years of splurging our cash is disappointing to hear. All talk, no action. On his watch KPTI has been DESTROYED as he fed everyone everyday catered free lunches, and splurged in so many ways including huge donations of our money that we didn't have. He's had no sense of urgency for years as he burned hundreds of millions of our money and handed us delay after delay without a trace of responsibility or regret. Arrogant and entitled, Paulson is NOT fit to lead the company even one more day, with or without data. He is a disgrace to us long term shareholders and a gift to short sellers, scums, cockroaches, vultures, sharks who've sucked our assets years after year on this man's watch.

1 · Reply

laaarsas May. 20 at 10:39 AM

$KPTI Have you all did it???

0 · Reply

celebratelife May. 19 at 8:55 PM

$KPTI

0 · Reply

laaarsas May. 19 at 12:49 PM

$KPTI Did you all do it?

1 · Reply

mich1282 May. 18 at 8:47 PM

$KPTI kind of wild this thing has taken a 21% hit since earnings with major data incoming and big tires accumulating

1 · Reply

laaarsas May. 17 at 4:02 PM

$KPTI I have called them. Still no answer. You have to call them. All of you.

0 · Reply

laaarsas May. 16 at 9:37 PM

$KPTI anyone got anything to say here?

0 · Reply

celebratelife May. 16 at 4:38 PM

$KPTI is on the verge of collapse with only a few months of cash left due to mismanagement and lack of financial discipline or sense of urgency for years. The Board is squarely responsible. Vote them out.

0 · Reply

hbkstockislife May. 16 at 1:45 PM

$KPTI can anyone let me know why this ASCO data I so important ..we already know the data correct like a month and half back ..just asking

2 · Reply

JFais May. 16 at 1:28 PM

Finishing up our weekly recap post: $KPTI double beat on Q1 report, "important presentation at ASCO", endometrial trial fully enrolled & on track for midyear readout $TMDX weakness due to trial delays & gross margin compression for several quarters (aggressively investing for future growth), temporary headwind from the Modernization Act Top 5 Holdings Channel: Feels like people starting to use AI for sharing portfolios, makes for really cool graphics helpful for idea generation (categorized by therapeutic area). Hat tip to @lfholt , @JoseRestonVA and @WassimLaroussi3 among several others (latter is cooking up a nifty tool for fund tracking if you haven't seen his feed lately)

2 · Reply

Karyopharm Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 1 day ago

Karyopharm Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 17, 2026, 7:00 AM EDT - 3 days ago

Karyopharm Therapeutics Slides: Corporate presentation

May 14, 2026, 1:10 PM EDT - 6 days ago

Karyopharm Therapeutics Q1 Earnings Call Highlights

2026-05-14T12:06:55.000Z - 6 days ago

Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)

2026-05-14T12:04:59.000Z - 6 days ago

Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M

May 14, 2026, 8:00 AM EDT - 6 days ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 6 days ago

Karyopharm Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 6 days ago

Karyopharm Therapeutics Slides: Q1 2026

May 14, 2026, 8:00 AM EDT - 6 days ago

Karyopharm Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:30 AM EDT - 6 days ago

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

May 12, 2026, 7:30 AM EDT - 8 days ago

Karyopharm to Participate at Upcoming Investor Conferences

May 7, 2026, 7:30 AM EDT - 13 days ago

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

2026-05-07T09:54:47.000Z - 13 days ago

Karyopharm price target raised to $13 from $8 at H.C. Wainwright

2026-05-04T20:43:12.000Z - 16 days ago

Karyopharm files $400M mixed securities shelf

2026-05-04T20:42:15.000Z - 16 days ago

Karyopharm files to sell 8.84M shares of common stock for holders

May 4, 2026, 8:00 AM EDT - 16 days ago

Karyopharm Therapeutics Registration statement: Registration filing

May 4, 2026, 8:00 AM EDT - 16 days ago

Karyopharm Therapeutics Registration statement: Registration filing

2026-04-27T10:52:35.000Z - 23 days ago

Karyopharm price target raised to $16 from $8 at Piper Sandler

Apr 21, 2026, 10:32 AM EDT - 4 weeks ago

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Apr 16, 2026, 7:00 AM EDT - 4 weeks ago

Karyopharm Therapeutics Slides: Corporate presentation

Apr 13, 2026, 8:00 AM EDT - 5 weeks ago

Karyopharm Therapeutics Proxy statement: Proxy filing

2026-04-07T15:11:06.000Z - 6 weeks ago

Karyopharm price target lowered to $16 from $23 at RBC Capital

2026-03-30T11:31:21.000Z - 7 weeks ago

Karyopharm price target lowered to $8 from $12 at Piper Sandler

2026-03-25T11:26:32.000Z - 2 months ago

Karyopharm price target lowered to $15 from $21 at Baird

2026-03-25T10:10:13.000Z - 2 months ago

Karyopharm price target lowered to $8 from $15 at H.C. Wainwright

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Transcript: Study result

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Press release: Study result

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Karyopharm Therapeutics Slides: Study result

Mar 24, 2026, 7:17 AM EDT - 2 months ago

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

2026-03-24T11:06:13.000Z - 2 months ago

Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint

2026-03-24T11:05:33.000Z - 2 months ago

Karyopharm announces $30M private placement

Mar 24, 2026, 7:01 AM EDT - 2 months ago

Karyopharm Announces $30 Million Private Placement with RA Capital

Mar 24, 2026, 7:00 AM EDT - 2 months ago

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

2026-03-09T20:20:12.000Z - 2 months ago

Karyopharm initiated with a Buy at Rodman & Renshaw

Mar 2, 2026, 4:05 PM EST - 2 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026, 9:00 AM EST - 3 months ago

Karyopharm Therapeutics Transcript: EGM 2026

Feb 12, 2026, 8:00 AM EST - 3 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2025

Feb 12, 2026, 8:00 AM EST - 3 months ago

Karyopharm Therapeutics Annual report: Q4 2025

Feb 12, 2026, 8:00 AM EST - 3 months ago

Karyopharm Therapeutics Earnings release: Q4 2025

Feb 12, 2026, 8:00 AM EST - 3 months ago

Karyopharm Therapeutics Slides: Q4 2025

2026-02-12T12:46:18.000Z - 3 months ago

Karyopharm reports Q4 EPS ($5.71) vs. ($3.67) last year

Feb 12, 2026, 7:30 AM EST - 3 months ago

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Feb 5, 2026, 7:30 AM EST - 3 months ago

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

2026-02-05T10:10:10.000Z - 3 months ago

Karyopharm initiated with an Overweight at Cantor Fitzgerald

2026-01-12T12:17:22.000Z - 4 months ago

Karyopharm sees FY25 revenue $145M, consensus $147.83M

Jan 12, 2026, 7:00 AM EST - 4 months ago

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Jan 9, 2026, 7:00 AM EST - 4 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 30, 2025, 7:00 AM EST - 5 months ago

Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 10, 2025, 12:00 PM EST - 5 months ago

Karyopharm Therapeutics Transcript: Baird's Biotech Discovery Series

Dec 8, 2025, 7:00 AM EST - 5 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 4, 2025, 10:30 AM EST - 5 months ago

Karyopharm Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 6 months ago

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

2025-11-04T14:50:10.000Z - 7 months ago

Karyopharm price target lowered to $19 from $30 at RBC Capital

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

Karyopharm Therapeutics Slides: Q3 2025

Nov 3, 2025, 7:00 AM EST - 7 months ago

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Nov 3, 2025, 7:00 AM EST - 7 months ago

Karyopharm Therapeutics Registration statement: Registration Filing

Nov 3, 2025, 7:00 AM EST - 7 months ago

Karyopharm Therapeutics Registration statement: Registration Filing

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 8, 2025, 7:00 AM EDT - 8 months ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Sep 10, 2025, 7:00 AM EDT - 9 months ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Karyopharm Therapeutics Slides: Q2 2025

Aug 11, 2025, 7:30 AM EDT - 10 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Karyopharm Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: FY 2025

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Corporate Presentation

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 9:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: AGM 2025

May 21, 2025, 10:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 1 year ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Karyopharm Therapeutics Slides: Q1 2025

May 12, 2025, 4:05 PM EDT - 1 year ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 1 year ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing

Mar 5, 2025, 12:00 AM EST - 1 year ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Annual report: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q4 2024

Feb 19, 2025, 7:30 AM EST - 1 year ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 1 year ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 1 year ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 1 year ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 16, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 9, 2024, 8:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 5, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Proxy statement: Proxy Filing

Dec 3, 2024, 11:30 AM EST - 1 year ago

Karyopharm Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 8:00 AM EST - 1 year ago

Karyopharm Therapeutics Slides: Q3 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Press release: Study Update

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Study Update

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 10, 2024, 9:00 AM EDT - 1 year ago

Karyopharm Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Karyopharm Therapeutics Slides: Q2 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 2 years ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 2 years ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 5, 2024, 1:00 PM EDT - 2 years ago

Karyopharm Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 1, 2024, 1:45 PM EDT - 2 years ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

celebratelife May. 20 at 3:04 PM

1 · Reply

laaarsas May. 20 at 10:39 AM

$KPTI Have you all did it???

0 · Reply

celebratelife May. 19 at 8:55 PM

$KPTI

0 · Reply

laaarsas May. 19 at 12:49 PM

$KPTI Did you all do it?

1 · Reply

mich1282 May. 18 at 8:47 PM

$KPTI kind of wild this thing has taken a 21% hit since earnings with major data incoming and big tires accumulating

1 · Reply

laaarsas May. 17 at 4:02 PM

$KPTI I have called them. Still no answer. You have to call them. All of you.

0 · Reply

laaarsas May. 16 at 9:37 PM

$KPTI anyone got anything to say here?

0 · Reply

celebratelife May. 16 at 4:38 PM

0 · Reply

hbkstockislife May. 16 at 1:45 PM

$KPTI can anyone let me know why this ASCO data I so important ..we already know the data correct like a month and half back ..just asking

2 · Reply

JFais May. 16 at 1:28 PM

2 · Reply

celebratelife May. 15 at 4:41 PM

$KPTI AS LONG AS RICHARD PARTY PAULSON IS CEO KPT IS DOOMED. FIRE HIS THAT ARROGANT ENTITLED INCOMPETENT VALUE DESTROYER'S ASS AND KPT WILL TAKE OFF. This shows two big blocks over 100k dumped today.

0 · Reply

elmono May. 15 at 4:25 PM

$KPTI shorters heaven today…..🙏 for all cheapies

1 · Reply

laaarsas May. 15 at 3:43 PM

$KPTI Here we go. People start to realise BICR PFS is shit.

1 · Reply

laaarsas May. 15 at 12:53 PM

$KPTI Fifty days. For 50 days the company has refused to respond. Has anything like this ever happened before?

0 · Reply

laaarsas May. 15 at 11:54 AM

$KPTI Where is it?

1 · Reply

MarketBeat May. 14 at 5:10 PM

https://marketbeat.com/a/8654805/ $KPTI Karyopharm Therapeutics Q1 Earnings Call Highlights

0 · Reply

laaarsas May. 14 at 4:11 PM

$KPTI Why the fuck did they not adress the BICR PFS in SIENDO? Honestly

0 · Reply

DeadManJoaquin May. 14 at 3:15 PM

$KPTI I've 2000 $2.50 calls expiring tomorrow. Was a tense hold for awhile. Whew

0 · Reply

Merlintrader May. 14 at 2:33 PM

$RGNX Three Biotech Earnings Reports, Three Different Catalyst Stories: Gene Therapy, Autoimmune Cell Therapy and Oncology in Focus — $RGNX, $CABA, $KPTI https://www.merlintrader.com/three-biotech-earnings-rgnx-caba-kpti-may2026/

0 · Reply

steven1x May. 14 at 2:17 PM

$KPTI any changes in OS?

0 · Reply

EarningsInsider May. 14 at 1:31 PM

https://www.marketbeat.com/earnings/reports/2026-5-14-karyopharm-therapeutics-inc-stock/ $KPTI Karyopharm Therapeutics Earnings Transcript

0 · Reply

steven1x May. 14 at 1:23 PM

$KPTI https://api-gw-prd.stocktwits.com/earnings-api/v1/documents/63dffb36-1f4d-4a12-99b6-9ea3485acce8/slides.pdf

1 · Reply

Market Cap	169.29M
Revenue (ttm)	146.07M
Net Income (ttm)	-196.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-134.21%
Debt to Equity Ratio	-0.45

Volume	658,500
Avg Vol	1,004,854
Day's Range	N/A - N/A
Shares Out	22.66M
Stochastic %K	33%
Beta	0.80
Analysts	Strong Sell
Price Target	$15.29